Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686068 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by VelaVigo Bio.
- Not yet
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
NCT07686068: Clinical Trial Phase 1 study, sponsored by VelaVigo Bio.
NCT07686068 is a Phase 1 study that has not yet begun recruiting, run by VelaVigo Bio. The registered enrollment target is 260 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (333% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07686068, a Phase 1 study, has not yet begun recruiting, sponsored by VelaVigo Bio.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
Primary Outcome
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
Interventions
- DRUG VBC106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-08-18 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
What is known before NCT07686068 opens enrollment
NCT07686068 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (333% higher).
The record links to 0 conditions, and to 1 intervention - of which VBC106 is the first listed.
NCT07686068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07686068 about?
NCT07686068 is a clinical study titled "First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors". This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to fu...
What is the current status of trial NCT07686068?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2026-08-18. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07686068?
The interventions under investigation include: VBC106 (DRUG).
Who is sponsoring clinical trial NCT07686068?
This trial is sponsored by VelaVigo Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07686068's enrollment target sits among peer trials
260 160th of 2000 higher than 1,834 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI